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The tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis in malignant cells,
while leaving other cells mostly unharmed. However, several carcinomas remain resistant to TRAIL. To
investigate the resistance mechanisms in TRAIL-stimulated human fibrosarcoma (HT1080) cells, we
developedacomputationalmodeltoanalyzethetemporalactivationprofilesofcellsurvival(IkB,JNK,p38)
and apoptotic (caspase-8 and -3) molecules in wildtype and several (FADD, RIP1, TRAF2 and caspase-8)
knock-down conditions. Based on perturbation-response approach utilizing the law of information
(signalingflux)conservation,wederivedresponserulesforpopulation-levelaveragecellresponse.Fromthis
approach, i) a FADD-independent pathway to activate p38 and JNK, ii) a crosstalk between RIP1 and p38,
and iii) a crosstalk between p62 and JNK are predicted. Notably, subsequent simulations suggest that
targeting a novel molecule at p62/sequestosome-1 junction will optimize apoptosis through signaling flux
redistribution. This study offers a valuable prospective to sensitive TRAIL-based therapy.
T
he search to induce apoptosis, or programmed cell death, in cancer cells has led to the emergence of a
new and fast growing field termed cancer immunology
1, also referred to as tumor immunology
2. Here, the
interactions between the immune system with malignant cancers have shown the suppression of disease
progression. Among the many immune factors found within the tumor microenvironment, the tumor necrosis
factor (TNF) family members are noted for their ability to induce cellular apoptosis
3. In particular, the TNF-
related apoptosis ligand (TRAIL), also known as Apo-2 ligand and TNFSF10, has received primal attention due
to its ability to recognize and induce apoptosis of tumors and metastases while leaving normal cells mostly
unaffected
4.
The endogenous TRAIL is prevalently found in several types of immune cells (e.g. macrophages, natural killer
cells, T-cells) and its expression can be elevated in these cells by infected agents, such as, through the Toll-like
receptor and the interferon gamma signaling pathways
5. TRAIL is known to bind with TRAIL-R1 (or death
receptor (DR) 4), TRAIL-R2 (or DR5), TRAIL-R3 (or decoy receptor (DcR) 1), TRAIL-R4 (or DcR2) and
osteoprotegerin. Notably, TRAIL-R1 and -R2 possess intracellular death domains and, subsequently, have the
ability to mediate TRAIL-induced apoptosis. The remaining receptors are decoys that compete for TRAIL,
thereby, possibly negatively regulate the effects of TRAIL-R1 and -R2 signaling
6.
TheimmunedefenseroleofTRAILwasshowntokillpathogen-infectedormalignantcells
7.Notably,increased
expressions of TRAIL-R1 and -R2 have been found on several kinds of tumor cells’ extracellular membrane with
corresponding increases in apoptosis compared with normal cells. The deficiency of TRAIL-R1 and -R2 has also
led to malignancy
8. Further investigations using TRAIL-induced apoptosis for effective control of cancer pro-
liferation have yielded successes at preclinical settings for certain cancer cells. In majority of cases, such as
melanoma and neuroblastoma, however, TRAIL stimulation has little or no effect
9.
The non-sensitivity of TRAIL-stimulated cancers occurs due to several factors including: very low expression
levels of TRAIL-R1 and -R2s, increased levels of DcR1, DcR2, elevated levels of negative regulators of
apoptosis
9 such as cFLIP, etc. On top of these, the upregulation of cell survival and proliferation pathways,
through mitogen-activated protein kinases (MAPK) and nuclear factor-kB (NF-kB) activations, are crucial for
the resistance
10.
More recently, to overcome resistance, TRAIL has been used in conjunction with other treatment strategies.
Several studies have made combination therapies with proteasome inhibitors, histone deacetylase inhibitors,
ionizing radiation etc., for enhancing apoptosis
11,12. Also, specific intracellular targets, such as tyrosine kinase
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survival of cancer
13,14. These works have focused on a single mode of
action by either targeting survival or apoptotic pathways. However,
as cancers are known to show high activities of both survival and
apoptotic pathways
15, it remains unclear whether the suppression of
survival or the enhancement of apoptosis, independently, will yield
optimal results. It is perhaps so that the clinical results so far have
only shown partial response in majority of cases and ask for a deeper
understandingofthesynergisticeffectofcombinatorialtreatments
16.
Thus, clear mechanistic insights into the conflicting roles of the cell
survival and apoptotic pathways triggered by TRAIL are required.
For example, when are cell survival and apoptotic pathways acti-
vated? Do they regulate each other? Are they induced at different
time points? Finding answers to these questions can provide an
improved strategy to treat cancers using TRAIL.
So,inspiteofnumerousstudiestargetingTRAILresistance,weare
stillfarfromsuccessfullyunderstandingandcontrollingthemechan-
isms for the resistance. Another possible reason may lie in the way
intracellular data are generated, analyzed and interpreted. For
example, many studies use single time point readout of survival or
apoptotic molecules to compare treated with untreated cancer cells.
Althoughsuchdataprovidequalitativesnapshotinformationofcan-
cer cells response to the treatments, they may not necessarily show
the overall effectiveness in time. For example, in lipopolysaccharide-
stimulated macrophages, we observed that molecules that are upre-
gulated (based on mRNA expressions) at early time points can
become downregulated at later time points
17. Thus, it is important
to rigorously analyze the temporal data generated by TRAIL-stimu-
lated experiments using multidisciplinary approaches.
Here, to shed light into the resistance mechanisms and to identify
an effective intracellular target for TRAIL-resistant human fibrosar-
coma (HT1080), we investigated, using a computational model, the
activation dynamics of several cell survival (IkB, JNK, p38) and
apoptotic (caspase-8, -3) signaling molecules. The model, based on
perturbation-responseapproach,doesnotrequirethefullknowledge
of all signaling species and their reaction kinetics. Rather, it uses
linear response rules, derived from the fundamental law of informa-
tion (signaling flux) conservation, to elucidate novel features of
population-level average cell signaling pathways and has been suc-
cessfully used in Toll-like receptors (TLRs) signaling studies
18–21.
Using the approach of comparing experimental data with model
simulations, firstly we uncover novel pathway features for TRAIL
signaling in HT1080 cells. Secondly, we evaluate the net effect of
cancer cell survival and apoptosis under various intracellular muta-
tionsbydevelopingatheoreticalcellsurvivalmetric(CSM).Usingthe
computational model together with CSM, our approach predicts an
optimal target for overcoming TRAIL resistance.
Results
Dynamic computational model for TRAIL-stimulated HT1080
cells. A previous experimental work on HT1080cells has shown that
TRAIL stimulation not only activate the apoptotic pathways (cas-
pases), but also display cell survival activities, through NF-kB and
MAPKs, resulting in the overt resistance to death
22. However,
the systemic understanding of the counterbalancing survival and
death mechanisms still remains unclear
23. For developing effective
strategies to control TRAIL resistant cancer cells, a mechanistic
understanding of the temporal activations of the cell survival and
apoptosis pathways is required.
To investigate the dynamical activations of cell survival (NF-kB,
MAPKs) and apoptosis (caspases) in TRAIL-resistant HT1080 cells,
we developed a computational model of TRAIL signaling (see text
below). The original model was developed using the widely accepted
TRAIL signaling topology: upon ligation of TRAIL, TRAIL-R1
(DR4) and TRAIL-R2 (DR5) form receptor clusters facilitated by
O-glycosylation and/or palmitoylation. This allows the intracellular
deathdomain of TRAIL-R1 and -R2to recruit FADD, caspase-8 and
cFLIP, collectively called the primary death-inducing signaling
complex (DISC). Still attached to the membrane, the DISC becomes
enriched in lipid rafts, subsequently allowing caspase-8 to interact
withCUL3/RbxI-basedE3ligasecomplex.Polyubiquitylationofcas-
pase-8 occurs and the ubiquitin-binding protein p62/sequestosome-
1 binds with caspase-8 to detach it from the DISC. Consequently,
caspase-8 interacts with RIP1, TRAF2 and IKK-c to form secondary
DISC,whichactivatesdownstreamNF-kB,MAPKs,andcaspase-3,a
member of the cysteinyl-aspartate-specific proteases, through the
extrinsic pathways
23–25 (Figure 1A). The static TRAIL topology was
converted into a dynamic computational model (see ‘‘Perturbation-
Response approach’’), where each species is connected to another by
first-order response equations and the parameters were chosen from
temporal experimental data (see ‘‘TRAIL Modeling Strategy’’ and
Figure 1B).
In recent years, there have been calls for understanding biology
including spatial and stochastic processes
26. This is especially
observed for single cell analysis where the heterogeneity of each
molecular component can result in distinct response profiles
betweencells
27.However,atpopulationlevel,manyofthedifferences
in single cell response profiles can be averaged out to reveal deter-
ministic patterns for the entire population. For example, the well-
coordinated response of cell populations, such as differentiation or
growth,demonstratesthatthesinglecellnoiseorheterogeneityeffect
could cancel out when ensembles of cells are formed to generate
a stable and robust response. Here, the data that is used to develop
the TRAIL model represents population level average response
(Figure 1B).
Perturbation-Response approach. At cell population level, mac-
roscopic descriptions of complex reaction mechanisms connect a
series of reacting species into well-defined ‘‘average’’ pathways.
The connectivity of the reaction species, in general, can be anti-
cipated to be governed by non-linear expressions as biology is a
complex system. Given a fixed perturbation to one of the species in
the connected system will result in propagation of response waves
through the connectivity.
Ingeneral,forsystemwithnspecies,thereactionmechanismsare:
LXi
Lt
~Fi X1,X2,::,Xn ðÞ , i~1,::,n ð1Þ
where the corresponding vector form of Eq. 1 is
LX
Lt
~FX ðÞ , F is a
vector of the unknown non-linear function which includes diffusion
and reaction terms, and X 5 (X1, X2, .., Xn) is the species response
profiles
28,29. For a fixed perturbation, the resultant changes in species
profiles can be written by X 5 X0 1 dX, where X0 is the reference
steady-state vectoranddXis the relativeresponse fromsteady-states
(dXt50 5 0).
When the actual reaction mechanisms are unknownor difficult to
solve analytically, Eq. 1 can be expanded into Taylor series:
LX
Lt
~
LFX ðÞ
LX
       
X~X0
dXz
LF2 X ðÞ
LX2
       
X~X0
dX2z::: ð2Þ
where F(X0) 5 0 at the steady-state X0 . Eq. 2 shows the presence of
first and higher-order terms to the response wave propagation
through the connected species. In such a discretized manner, we
can investigate which of the individual terms become dominant to
a given perturbation. This approach is unlike the conventional ‘‘bot-
tom-up’’ strategy of defining each reaction equation through the
stoichiometry of reactions, isolated kinetics and in vitro defined
parameters.
InourpreviousworksonTLRsignaling
18,19,21,theuseoffirst-order
response equations was sufficient to reveal experimentally verifiable
novel signaling features for the macrophage population response. In
www.nature.com/scientificreports
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state, when the higher-order terms become negligible, that is,
LdX
Lt
?
ddX
dt
<
dFX ðÞ
dX
       
X~X0
dX. That is, from our ‘‘top-down’’
approach,wefoundthatthefirst-ordertermisthemostdominantin
population-level TLR signaling. Such macroscopic first-order terms
are not necessarily restricted to reaction terms only, they can also
representtheaveragingeffectofspatialinformationsuchasdiffusion
and transport mechanisms. For example, we showed that the endo-
cytosis of TLR4 involving diffusion and transport
30, can be approxi-
mated by several first-order terms
18.
The amount of fixed perturbation chosen for the model depends
ontheexperimentallystimulatedconcentration,whiletheparameter
values, or the elements of the Jacobian or linear stability matrix
J~
dFX ðÞ
dX
       
X~X0
,arechosenbyfittingdXwithcorrespondingexperi-
mental profiles along the activation topology. Thus, each species in
our model can represent a signaling molecule, different modified
state of a molecule (e.g. ubiquitinated state) or asignaling event such
as diffusion, endocytosis, etc. That is, each species in our signaling
network does not necessarily represent a specific molecular species.
For illustration, in a pathway q1Rq2Rq3Rq4Rq5, q1 to q5 can
each be a different protein or the same protein at different stages
insignaling,forexample, (q1)beinginternalized(q2),transported to
a different organelle (q3), ubiquitinated (q4) and become part of a
protein complex (q5).
Thus, unlike typical signaling models, which often use kinetic
equations to model the dynamics, our perturbation-response
approach considers the network as a sequence of events rather than
just molecules. As signaling networks are largely not fully under-
stood, this difference is crucial as it prevents rigidly fixing the
network topology, and allows it to be modified according to experi-
mental data so as to prevent overfitting problems and to identify
novelfeaturesofsignalingnetworks.Inaddition,assignalingprocess
involve large number (thousands) of intracellular molecular activa-
tions
31, it is currently not plausible to model the dynamics of all
possible reactions with the generally limited data. To overcome such
difficulties, our approach permits the lumping of several molecules
into a species and the averaging nature of the response equations
does not require detailed kinetics. In this way, our model does not
become a comprehensive representation of entire signaling process,
however, it allows the identification of overtly missing key features.
Therefore, for TRAIL signaling, it would not be appropriate to
develop a hard-wired model based on wildtype data alone. For
example, our previous works on TLR signaling have demonstrated
that an initial model developed using up-to-date literature topology
and fitted with wildtype data would not be sufficient to simulate
other mutant conditions, e.g. in MyD88 or TRAF6 knock-outs
18,19,21.
Figure 1 | TRAILsignalingpathway and experimental activation profilesof signaling molecules. (A)Schematic topology of TRAIL signaling pathway.
See maintext for details. (B) Experimental activation profiles of p38, IkB, JNK, caspase-8 and -3 in wildtype, RIP1 KD*, FADD KD*, caspase-8 KD*,
andTRAF2KDinarbitraryunits(a.u.)att50,10,30,60**and120 minafterTRAILstimulationofHT1080cells.Theoriginalsourcewasobtainedfrom
Figure 3A of ref. 22 and was processed through imageJ (see Methods). *data is unavailable for caspase-8 and -3, ** available only for caspase-8 and -3.
Note: interpolated dotted lines between experimental data points are inserted as a guide, they might not represent the actual temporal dynamics.
www.nature.com/scientificreports
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developedusingwildtypedata,andtestitwithotheravailableexperi-
mentalconditions. Byreducing wildtypeparameter spaceandallow-
ing the topology to carefully evolve using response rules (see below),
from the law of information conservation and first-order response,
we are able to successful produce a model that simulates multiple
experimental conditions.
TRAILmodelingstrategy.TodevelopandanalyzetheTRAILmodel,
we created a computational modeling framework (Figure 2). An
initial model is constructed using the known TRAIL topology and
theparameters ofthefirst-orderresponseequationsarechosen,with
the aid of a genetic algorithm
32, to fit the semi-quantitative data of
each tested molecule’s activation profile (e.g. p38, JNK, etc.) in wild-
type (Methods). Once the simulation for all tested molecules fit
reasonably well in wildtype, we next test their validity in other
mutant conditions (RIP1 KD, FADD KD, etc.). If the simulations
arenot satisfactory inany experimental condition (basedon the area
between the experimental profiles and simulations curves, see
Methods), we modify the current TRAIL topology according to the
responserules.Forexample,inwildtype,ifatimedelayisobservedin
the experimental activation onset compared with simulation, then
according to response rule 1 (see below and Figure 3), additional
intermediary first-order terms are added to provide delay. The pro-
cess of modifying TRAIL topology and parameter values for each
molecule and in each condition is done iteratively until all tested
molecules are able to successfully reproduce experimental data in
all tested conditions (Figure 2).
Overall, we utilized 5 experimental conditions (wildtype, RIP1
KD, FADD KD, caspase-8 KD and TRAF2 KD) to generate a single
robust model that simulates 5 molecules (IkB, JNK, p38, caspase-8
and -3) over 5 measured time points (0, 10, 30, 60 and 120 min) for
TRAIL-stimulated HT1080 cells (Figure 1B). This is in contrast to
mostcomputationalstudies,whichonlyusewildtypedatatodevelop
signaling models. Notably, as a result of our approach, we are able to
modify the initial literature model to a final one (consisting of 32
specieswith39reactions)indicatingseveralnovelfeaturesforTRAIL
signaling (Table 1).
Figure 2 | ComputationalmodelingframeworkforTRAILsignaling. Parametersofthe initialmodelbasedontheoriginal topology(1)aredetermined
by overall fitting of experimental data using a genetic algorithm (GA, see Methods) for all molecules (i51,2,..n) and at all conditions (k50,1,…m), here
n55 and m54. (2). If the overall error E5max(ei,k) between experimental and simulation profiles is higher than the set tolerance (3) (see Eq. 5) in
Methods), the model isnot acceptable. As the next step, the n molecules’ activation profiles are ranked from the one showing highest (i51) to the lowest
(i5n) error (4)for individual molecule’s(5) bestfitting inwildtype (6) andmother experimental conditions (69).Ifthe simulation ofthei
thmoleculefit
reasonably in the k
th condition (individual error ei,k # 0.15) (7), we check the next condition (k11), else we modify the current topology according to
responserules(8)(seeFigure3)andrestarttheprocedurefromwildtypeconditionagain(6).Ifallmconditionsfitforthei
thmolecule(9–10)withoutany
changesappliedtothetopology,weproceedtothenextmolecule(i11)(11).Ifanychangeisnecessarytothetopology,theparametershavetoberefitted
for all molecules from the first molecule (i51). The whole procedure is repeated until the resultant model fit all experimental profiles of the n molecules
within the error tolerance (12).
www.nature.com/scientificreports
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initial signaling topology to infer novel network features by deriving
10 main response rules from the law of signaling flux conservation
and first-order average response to pulse perturbation (Figure 3A–
C). Analyzing time to activation: Rule 1, Time delay: by comparing
the time to reach peak activation, any time delay in target signaling
molecule’s activation represents ‘missing’ cellular features such as
directedtransportmachinery,proteincomplexformation,andnovel
molecular interactions. Rule 2, Rapid flux: when the activation of a
downstream molecule is noticeably quicker than the experimental
activation, a novel rapid bypass pathway is inferred. Analyzing peak
activation levels: Rule 3, Missing flux: when the removal of a mole-
cule along a pathway does not completely abolish its downstream
intermediates, the presence of a novel bypass is indicated. Rule 4,
Signaling Flux Redistribution (SFR): At pathway junctions, the
removal of a molecule enhances the entire alternative pathways.
Rule 5, Lack of SFR: At pathway junctions, the removal of a molecule
does not enhance the alternative pathway, suggesting novel i) inter-
mediate(s) between the removed molecule and the pathway junction
orii)pathwaylinkbetweentheremovedmoleculeandthealternative
pathway. Rule 6, Dominant and Recessive flux: quantifies each path-
way branch by comparing activation levels between wildtype and
mutants data. Analyzing activation patterns: Rule 7, Reversible flux:
when a response profile show limiting decay that cannot be modeled
by first-order decay, the presence of reversible step is expected to
produce limiting decay
33. Rule 8, Superposing flux: when a response
profileshowmultiplepeaks,thesuperpositionprincipleindicatesthe
presence of novel i) bypass pathway from the same source or ii)
alternative pathway with delayed response. Rule 9, Continuous flux:
when a response profile shows a continuous increase of activation
not following pulse perturbation response, this indicates additional
continuousfluxfromfeedbackmechanismssuchasposttranslational
effect or secondary signaling
34. Rule 10, Oscillations: When oscillat-
ory response is observed, i) continuous feedback loop
35 is suggested
for regular dynamics and ii) non-linear effects such as chaotic bio-
chemical dynamics
36 are inferred for irregular dynamics.
Simulations of initial TRAIL signaling model. First, we performed
parameter fitting of the initial model (Figure 4A) with the wildtype
data (Figure 1B). Several parameter sets were examined so that the
simulations could match the experimental profiles. The IkB, JNK,
caspase-8and-3simulationswereabletosuccessfullyfitwithexperi-
mental profiles, however for p38, experiment shows rapid activation
compared with the model simulation (Figure 4B, wildtype).
Next, we compared the model simulations for other mutant con-
ditions (RIP1 KD, FADD KD, caspase-8 KD and TRAF2 KD) and
notice that although IkB, caspases-8 and -3 simulations recapitulate
experiments in all conditions, the simulations of p38 and JNK
activations are not satisfactory (Figure 4B). RIP1 KD shows
impaired activation of p38 compared to wildtype, however, in silico
RIP1 KD simulation shows similar levels to wildtype at 120 min
(Figure1Band4B,RIP1KD).Furthermore,thesimulationproduces
Figure 3 | Response rules to modify signaling topologies when the first
molecule isperturbed. (A)Analyzingtimetoactivation:Rule1,Timedelay
andRule2,Rapidbypass,(B)Analyzingpeakactivationlevels:Rule3,Missing
flux,Rule4,SignalingFluxRedistribution(SFR),Rule5,LackofSFRandRule
6, Dominant and Recessive flux, (C) Analyzing activation patterns: Rule 7,
Reversibleflux,Rule8,Superposingflux,Rule9,Continuousflux,andRule10,
Oscillations.Seemaintextfordescriptions.Notethatrules1–6aredeveloped
fromfirst-orderresponseandthelawofsignalingfluxconservationinpulse
perturbation. Rules 7–10 are introduced to interpret any non-linear
response or those that do not obey the law of conservation. These rules are
not exhaustive and can possibly be further categorized if detailed
experimental data for each molecule is available. The rules serve as guide to
modify the overt topology highlighting the key missing features only.
www.nature.com/scientificreports
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to experiment.
For FADD, caspase-8 and TRAF2 KDs, in contrast to experi-
mental profiles (Figure 1B), the simulations failed to show any p38
or JNK activations (Figure 4B). Collectively, the TRAIL model
developed using the current topology reasonably simulates IkB, cas-
pase-8 and -3 temporal activation profiles in all KD conditions,
however, it fails to capture the dynamics of p38 and JNK.
Revealing novel features of TRAILsignaling using response rules.
Toovercometheshortfallofourmodelsimulationsusingthecurrent
TRAIL topology, we utilized the response rules, so as to modify the
network to investigate whether the model simulations could be
improved, especially for p38 and JNK profiles.
Analyzingp38dynamics.InwildtypeandRIP1KD,wenoticep38is
experimentally activated within 10 min after TRAIL stimulation,
whereas, in model simulations it takes at least 20 min (Figure 4B
and 5A, M0). According to response rule 2, this can be achieved
through introducing a novel rapid bypass pathway to activate p38
more directly and specifically, perhaps not involving the primary or
secondary DISC as these may take longer activation times. Adding
thenovelbypassfromTRAIL-R1toMKK3/6producedagoodmatch
between simulations not only for wildtype data, but also for FADD
and caspase-8 KDs (Figure 5B, M1). Note that the novel bypass is
not sensitive whether the origin starts from TRAIL-R1 or the recep-
tor process terms. However, adding a bypass downstream, from
FADD onwards, incurs noticeable delay in p38 activation (data not
shown). Hence, we call this novel bypass as FADD-independent
pathway.
For RIP1 KD, although the delay activation is succumbed, the late
phase peak activation (at 120 min) is enhanced in simulations and
for TRAF2 KD, the p38 activation is still under predicted at 120 min
(Figure 5B). Response rules 5i and 5ii suggest that RIP1 activates
p38 so that its removal will negatively affect p38 activation. The
inclusion of this feature alone was sufficient to reasonably match
experimental and simulation results for both RIP1 KD and TRAF2
KD (Figure 5C, M2).
Analyzing JNK dynamics. Using the updated model, we next inves-
tigated JNK dynamics. This time, the JNK simulation for wildtype
and RIP1 KD is quicker than experimental profiles (Figure 5D, M2).
Hence,accordingtoresponserule1,weaddedadditionalnovelinter-
mediates(proteins,complexformation,etc.)specificallytoJNK.This
improved the JNK simulations, however, for FADD and caspase-8
KDs, the JNK dynamics are still absent (Figure 5E, M3). Utilizing
Table 1 | ThefinalizedTRAILmodelreactionsandparameters.NotethattosimulateeachKDcondition,weimposednullparametervalue(s)
for all reaction(s) involving the KD molecule.
Reaction/process k (1/s) Remarks
1 Apo2/TRAIL R TRAIL receptor 8.13E-3 Binding of TRAIL ligand to receptor
2 TRAIL receptor R Receptor process 1 8.17E-3 O-glycosylation, internalization of receptors, formation of
lipid rafts, etc. 3 Receptor process 1 R Receptor process 2 7.89E-3
4 Receptor process 1 R Y 1.04E-3 Activation of novel molecule Y
5Y R MKK3/6 4.31E-1 Rapid activation of MKK3/6 via Y
6 Receptor process 2 R FADD 1.08E-3 FADD binds to TRAIL receptors
7 FADD R pro-caspase-8 1.06E-3 pro-caspase-8 binds to FADD
8 pro-caspase-8 R CUL3 1,99E-3 Activation of CUL3
9 pro-caspase-8 R c-FLIP 1.00E-3* Activation of cFLIP (*arbitrary value)
10 CUL3 R Ubiquitination of caspase-8 1.00E-2 Ubiquitination of caspase-8
11 Ubiquitination of caspase-8 R p62 9.92E-1 Activation of p62/sequestosome
12 Ubiquitination of caspase-8 R TRAF2 8.67E-2 Activation of TRAF2 by pro-caspase-8
13 p62 R Z 3.09E-1 Activation of novel molecule Z by p62
14 p62 R RIP1 6.77E-2 Activation of RIP1 by p62
15 p62 R caspase-8 (active form) 2.72E-2 Activation of caspase-8 (cleaved)
16 caspase-8 (active form) R tBid 1.13E-5 Activation of tBid by caspase-8
17 caspase-8 (active form) R caspase-3 1.48E-6 Activation of caspase-3 (extrinsic pathway)
18 tBid R mitochondria 5.09E-2 Apoptotic intrinsic pathway via tBid
19 mitochondria R Cytochrome C 2.64E-1 Activation of Cytochrome C
20 mitochondria R Smac 2.79E-1 Activation of Smac
21 Cytochrome C R caspase-3 2.81E-1 Activation of caspase-3 via apoptosome
22 Smac R caspase-3 1.68E-1 Smac-dependent activation of caspase-3
23 caspase-3 R Apoptosis process 8.85E-3 caspase-3 depletion term
24 RIP1 R IKK 4.00E-4 Activation of IKK by RIP1
25 RIP1 R MKK3/6 5.04E-1 Activation of MKK3/6 by RIP1 (novel)
26 IKK R IkB 3.45E-1 Activation of IkB by IKK
27 IkB R NF-kB 8.99E-4 Activation of NF-kBb yI kB
28 NF-kB R Survival process 1.00E-1* NF-kB depletion term (*arbitrary value)
29 TRAF2 R MKK3/6 7.24E-5 Activation of MKK3/6 by TRAF2
30 TRAF2 R MKK4/7 2.63E-6 Activation of JNK pathway by TRAF2
31 MKK3/6 R p38 2.37E-4 Activation of p38 by MKK3/6
32 p38 R Survival process 1.31E-5 p38 depletion term
33 Y R Z 3.07E-1
Intermediates for delayed JNK activation
34 Z R X1 8.76E-4
35 X1 R X2 3.18E-3
36 X2 R X3 7.48E-3
37 X3 R MKK4/7 2.21E-3 Activation of JNK through bypass
38 MKK4/7 R JNK 1.81E-4 Activation of JNK by MKK4/7
39 JNK R Survival process 2.36E-4 JNK depletion term
Highlighted rows indicate novel features of the TRAIL signaling pathway.
www.nature.com/scientificreports
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way for p38 to also activate JNK. Thus, we introduced a novel mole-
cule Y to branch from TRAIL-R1 to p38 and JNK and specifically
inserted the additional novel intermediates between Y and JNK via
MKK4/6.
This procedure significantly improved the JNK simulations in
wildtype, RIP1 KD, FADD KD and caspase-8 KD, but not in
TRAF2 KD (Figure 5F, M4). To achieve specific activation of JNK
inTRAF2KD,werequireabypassfromp62tonovelmoleculeZ(one
of the novel intermediate predicted above) on the FADD-independ-
ent pathway to activate JNK (response rules 3 and 4). Overall these
modifications, based on the response rules, to the initial model
remarkably recapitulate IkB, p38, JNK, caspase-8 and -3 activations
inalltestedexperimentalconditions(wildtype,RIP1KD,FADDKD,
caspase-8 KD, and TRAF2 KD) with a good degree of consistency
(Figure 1B, 5G and 6A, M5).
Next, adopting response rule 6, we evaluated the relative signifi-
canceofeachnovelnetworkfeatures.Basedonthemodelsimulation
levels, the FADD-independent pathway contributes about 17% and
43% of total JNK and p38 activations, respectively, the RIP1 to p38
crosstalk provides about 45% flux for p38 activation. The bypass
from p62 to molecule Z provides about 82% flux to JNK, whereas
TRAF2 provides about 1% flux to JNK, and the TRAF2 to MKK3/6
axisprovideabout12%fluxtop38.Thus,RIP1iskeyforp38andZis
crucial for JNK activation.
In summary, we propose: i) a FADD-independent pathway to
activate p38 and JNK, bypassing the primary and secondary DISC
and through novel molecules Y and Z, ii) a crosstalk between RIP1
and p38 via MKK3/6, iii) a crosstalk between p62 and JNK via mole-
cule Z, and iv) intermediary step(s) or molecule(s) upstream of JNK
(Figure 6B).
Identifying in silico targets for enhancing cell death in HT1080
cells. To identify a promising target for overcoming TRAIL resist-
anceinHT1080cellpopulations,weusedtheupdatedTRAILsignal-
ing model, which simulates multiple experimental conditions. We
next wondered the roles of the novel molecules Y and Z in the
survival and apoptosis activities, and were interested to check
whether any of them could potentially be a crucial target for enhan-
cing cell death.
To investigate this, we examined the population level survival
ratios (SRs) for wildtype, FADD KD, TRAF2 KD and RIP1 KDs,
which are known to be about 59, 76, 28 and 18%, respectively for
TRAIL-stimulated HT1080 cells (see Figure 3C of ref. 22). Since our
modelsimulatessignalingmolecules’dynamicsanddoesnotdirectly
predict SR, to evaluate the SRs for Y and Z KDs, we developed a link
between SR and the survival and apoptotic molecules’ temporal
activation profiles (see Methods).
As area under each apoptosis and survival molecule’s activation
profile with time indicates an intensity measure of its respective
process, we used this to estimate a link with the SR. In order to
perform this, we introduce a novel theoretical metric, CSM, which
compares the area under curves of survival (IkB, JNK, p38) and
apoptotic (caspase-8 and -3) molecules and links it to SR (see
Methods).TheCSMevaluatestheneteffectofsurvivalandapoptosis
activations. A positive CSM indicates net survival mode and a nega-
tive CSM indicates net apoptosis mode.
We next performed in silico KDs of Y and Z molecules, simulated
IkB, JNK, p38, caspase-8 and -3 and evaluated their resultant CSMs
and SRs (Figure 7A–C). Notably, we observe among all investigated
KDs, the X KD results in the most negative CSM and the least SR
(with only about 5% surviving cells compared with 18% and 36% for
RIP1andYKDs,respectively,Figure7B–C).Thisisbecause,through
Figure 4 | Simulation of initial TRAIL signaling model. (A) Static topology of the TRAIL signaling pathway used in developing our computational
model. Note that we lump the similar effects of DR4/5 as TRAILR1/2, and ignore the response of DcR1/R2/OPG. Also, note that we include molecular
conditionssuchasreceptorclusteringasadditionalfirst-orderterms.(B)Comparisonofsimulations(solidlines)withexperimentaldata(dottedlines)in
wildtype,RIP1KD,FADDKD,caspase-8KD*andTRAF2KDinarbitraryunits(a.u.).Theerrorei,kbetweensimulationsandexperimentaldataforthei
th
moleculeinthek
thconditioniscalculatedbasedontheareabetweenexperimentalandsimulationcurves(seeEq.5inMethods).*caspase-8KDalsorefers
to pro-caspase-8 KD.
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morethanthesurvivalmolecules(Figure7A).Thus,ZKDshowsthe
most desirable outcome of maximizing cell death in all tested con-
ditions, making it clearly the best target candidate for TRAIL-
resistant HT1080 cells.
Toverifyouroverallresult,weperformedourownexperimentson
wildtypeTRAIL-stimulatedHT1080cells.Althoughweareunableto
perform experiments on the still uncharacterized Z KD cells, we
wanted to check the result of wildtype cells to TRAIL stimulation.
Notably, we successfully reproduced approximately 60% SR for
1000 ng/mL of TRAIL stimulation (compare Figure 1A of ref. 22
with Figure 7D). The validation of wildtype data demonstrates that
our average response model can be legitimately used to identify an
appropriate candidate, through computational simulations, for
enhancing TRAIL-based strategy.
Discussion
Over the last decade, there has been great interest leading to numer-
ous studies focusing on the usage of TRAIL, due to its ability to
trigger the apoptotic pathways, as a strategy to fight the progression
ofcancer.Althoughsuccessfulincertaincancertypes,TRAILhasnot
become a general candidate as many types of cancers are able to
evadeTRAIL’sapoptoticproperty.Althoughrecentworkshaveshed
light into the resistance mechanisms in TRAIL-based therapies
37,
Figure 5 | RevealingnovelfeaturesofTRAILsignalingusingmodelingstrategyandresponserules. Modelsimulationscomparedwithexperiments.For
p38,(A)M0,theinitialmodel,(B)M1withtheadditionofarapidbypass,and(C)M2withtheadditionofamissinglinkbetweenRIP1andp38pathway.
ForJNK(D)M2,(E)M3withintermediatestointroducedelayinactivation,(F)M4withamissinglinkfortheactivationofJNKinFADDandcaspase-8
KDs, and (G) M5 a missing link between p62 and JNK pathway to show enhancement through SFR in TRAF2 KD.
www.nature.com/scientificreports
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apoptoticpathwaysandfindingwaystosensitizeTRAIL-basedstrat-
egy remain poor.
Drugs that upregulate TRAIL receptors (e.g proteasome inhibi-
tors) in resistant cancers may not be effective as they are likely to
enhancebothcellsurvivalandapoptoticpathwayswiththeneteffect
not necessarily enhanced cell death. Further studies on using com-
binatorial treatment of TRAIL with downstream targets that selec-
tively suppress cell survival, such as NF-kB and MAP kinases
inhibitors, or enhancing apoptosis by suppressing the suppressors
of caspases have recently been investigated
12. The reduced cell sur-
vival activity or increased apoptosis produced, generally, an increase
intheneteffectof celldeath, providing goodprospective forincreas-
ing the efficacy of TRAIL-based strategies. However, these strategies
have focused on suppressing either the cell survival or apoptosis
activity, independently. It remains unclear which strategy among
these is optimal for the various TRAIL-resistant cancer types and,
hence, we require a strategy that considers dual mode of suppressing
the survival and enhancing the apoptosis pathway simultaneously.
Here, we report a systemic strategy that considers both the cell
survival and apoptotic dynamics to provide a more mechanistic way
to target TRAIL resistance. Our dynamic computational approach,
successful to model TLR
19 and TNF
34 pathways, is used to examine
the signaling mechanisms of NF-kB, MAP kinases and caspases
activations in TRAIL-stimulated HT1080 cells. Starting from a
literature curated generalized TRAIL signaling topology, firstly,
using response rules we infer novel features, namely i) a FADD-
independent pathway(s) to activate p38 and JNK, bypassing the
primary and secondary DISCs and through novel molecules Y and
Z, ii) a crosstalk between RIP1 and p38 via MKK3/6, iii) a crosstalk
between p62 and the JNK pathway, and iv) intermediary step(s) or
molecule(s) upstream of JNK (Figure 6B). These inclusions are
necessary for the computational model to successfully recapitulate
experimental outcome in all investigated conditions (wildtype, RIP1
KD, FADD KD, caspase-8 KD, and TRAF2 KD).
Secondly, to determine the best strategy to induce apoptosis in
TRAIL-resistant HT1080 cells, we investigated the net effect of
NF-kB, MAP kinases and caspases activations by evaluating their cell
survivalmetric,CSM,andmakingalinktothesurvivalratios(SRs)fo r
various KD conditions. Overall, our simulations suggest that the
optimaltargetisthenovelmoleculeZ,wherebyitsremovalispredicted
to produce about 95% HT1080 cell population death (Figure 7C).
Recent studies have indicated the roles of PI3K, Akt and MADD
for TRAIL resistance
38,39. We believe that these may belong to the
novel FADD-independent pathways, and one of these could well
represent the molecule Y. On the other hand, the novel molecule
Z,whichisactivatedbyp62tospecificallyactivateJNKinourmodel,
acts like a connector between the primary and secondary DISC.
Performing a search of the protein-protein interaction database
40
forp62interactingpartners,weobtainproteinkinaseC(PKC)family
members as likely candidates. Further literature search supports
PKC-f
41 as a possible candidate.
It is important to note that although our average response model
may not pinpoint a specific molecular target exactly, nevertheless, it
will be worthwhile to investigate molecules that interact with p62 for
the search for optimal target for effective cell death in TRAIL-resist-
ant HT1080 cells. Taken as a whole, the approach presented here
provides a promising contribution towards systemically analyzing
the dynamics of cell survival and apoptotic pathways, for the
sensitization strategy for TRAIL-based cancer therapy.
In this paper, we show that novel features of the TRAIL signaling
can be revealed through the law of conservation and first order
response equations. From this result, we theoretically demonstrate
that targeting a molecule at the survival and apoptosis pathway
junction can provide an optimal solution to treat TRAIL-resistance.
ItsuppressesJNKand,atthesametime,enhancescaspasesactivities.
Figure 6 | Simulations of the proposed TRAIL signaling topology. (A) Comparison of M5 simulations (solid lines) with experimental data (black
points) in wildtype, RIP1 KD, FADD KD, caspase-8 KD and TRAF2 KD. (B) Static topology of the proposed model for TRAIL signaling pathway.
Modifications are indicated by blue arrows.
www.nature.com/scientificreports
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molecular constituents
42, issues of heterogeneity
43, spatio-temporal
effects
44 such as diffusion and crowding within cells, are likely to
make the TRAIL signaling response non-linear and difficult to con-
ceptualize computationally. In contrary, our data suggests that cells,
asapopulation,areabletodiscardindividualdifferencestoachievea
globalaverage response that follows simple rules
20. This is clearly the
underlyingsuccessthatourfinalfirst-orderresponsemodelisableto
simulate multiple experimental conditions.
Although we do recognize that biological complexity such as
heterogeneity and fluctuations or noises observed at single cell
resolution
45 are important, at the same time we do need to accept
that biology, like any other complex system, possesses both micro-
scopic (single cell) and macroscopic (population average cell)
dynamics
20. Thus, it is necessary to treat the two dynamics distinct
and investigate their individual merits. For example, stochastic fluc-
tuations are necessary to induce probabilistic differentiation from
genetically identical cells, allowing multi-cellular organisms to
switch fates and states to yield diversity, such as for development
or stress, which, otherwise, may be impossible from a purely deter-
ministic system
46,47. On the other hand, the well-coordinated
response of cell populations, such as differentiation or growth,
demonstratesthatthesinglecellnoisecouldcanceloutwhenensem-
bles of cells are formed to generate a stable and robust response. For
instance, the observation of guided average behavior in the syn-
chronizationofneuronalsignaling
48,persistencemechanismsofbac-
teria
49 and collective decisions in ants
50 are all noteworthy.
Inthefuture,assinglecelltechniquescontinuetomakeimpressive
progress
51,itwillbeinterestingtocomparethesinglecelldynamicsof
HT1080 cells in wildtype and PKC-f mutants with the population
Figure 7 | Identifying key target for sensitizing TRAIL resistance. (A) Simulation profiles of p38, JNK, IkB, caspase-8 and -3 in Y and Z KDs. (B) Cell
survival metric (CSM) for all KDs. (C) Survival ratio, SR, (experimental versus evaluated, from t 5 0 to 120 min) in all conditions. Evaluated data is
obtained using experimental data of RIP1 and FADD KDs (see Methods). (D) Wildtype HT1080 and HT29 (control) cells shows 60% and 95% survival,
respectively, for 1000 ng/mL of TRAIL stimulation.
www.nature.com/scientificreports
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heterogeneous single cells responses
43 in TRAIL signaling could be
guided to provide apossible 100%cell death, atleast inadish. In this
light, large-scale tumor sequencing data
52 and the study of single cell
noise
53 will be critical to enhance our modeling aspects further to
generate and investigate single cell response models.
Methods
Experimental data of cell survival and apoptosis molecules. We utilized time-
course experimental data
22 of IkB, JNK, p38, caspase-8 and -3 in wildtype, RIP1 KD,
FADD KD, caspase-8 KD, and TRAF2 KD of HT1080 cells with 1000 ng/ml of
TRAIL stimulation. The activation levels of IkB, JNK, p38, caspase-8 and -3
(Figure 1B) were quantified from the western blots data using ImageJ
(http://rsbweb.nih.gov/ij/) and the normalized experimental value of the i
th molecule
in the k
th condition (wildtype (WT), RIP1 KD, FADD KD, TRAF2 KD) at time t is
evaluated as:
E^ XPi,k(t)~
EXPi,k(texp){EXPi,k(0)
max(EXPi,WT(texp){EXPi,WT(0))
, texp~ 0,10,30,60,120 fg ð 3Þ
where EXPi,k(texp) is the raw experimental value obtained from quantification, and
max EXPi,WT texp
     
indicates the maximum value obtained in wildtype condition.
Values lower than 0.05 are likely to possess significant signal-to-noise ratio and,
therefore, noted as zero. Simulations values of the i
th molecule in the k
th condition are
also normalized to wildtype data such as:
S^ IMi,k(t)~
SIMi,k(t)
max(SIMi,WT(texp))
, texp~ 0,10,30,60,120 fg ð 4Þ
Note texp560 min is available only for caspase-8 and -3.
Parameterfittingandfitnessofsimulations.Thefittingofthereactionsparameters
of a given topology is obtained by minimizing the error between experimental and
simulation profiles of all investigated molecules. We used a genetic algorithm where
the fitness function f is given by:
f~
X
i
X
k
ei,k,ei,k~
Ð tmax
0 S^ IMi,k{E^ XPi,k
  
dt
Ð tmax
0 E^ XPi,kdt
ð5Þ
andei,k istheerrorbetweentheexperimentalandsimulationcurvesofthei
thmolecule
in the k
th condition represented by normalized area between the experimental and
simulation curvesandtmax~120min.Thealgorithmevolvestheparametersetsfrom
one generation to the next by the operations of selection, crossover and mutations
32.
The model is considered acceptable when the tolerance is set for max(ei,k)ƒ0:15. To
avoidlocalminima,thealgorithmisperformedmultipletimesinmultipleconditions.
Flow cytometry analysis. HT1080 cells were cultured in 12 well plates (60000 cells/
well)andincubated for24 hours.HT29cells(negative control)wereincubatedinthe
same manner. Cells were transferred to a culture medium containing TRAIL/Apo2L
(0 and 1000 ng/mL) and incubated for 18 hours, then washed using Phosphate
buffered saline (PBS) solution, detached from the plate using Trypsin-EDTA and
centrifuged. Cell pellets were re-suspended in 200mL 1x Binding buffer, 5mL
AnnexinV-FITC and 10mL Propidium Iodide, and incubated at room temperature,
protectedfromlightfor15 min.Cellsuspension waspipettedintoPolyRoundTubes
through cell-strainer cap, then fluorescence intensity was measured using an EPICS
XL flow cytometer. TRAIL stimulation did not induce apoptosis of HT29 cells
(negativecontrol).Ontheotherhand,40%ofHT1080cellsunderwentapoptosisafter
18 hours upon TRAIL stimulation (1000 ng/ml) (Figure 7D).
Cell Survival Metric (CSM) and Survival Ratio (SR). Evaluating the level of each
survival and apoptotic molecule, independently, may not truly reflect the optimal
conditions for determining cell death. For example, by just analyzing the levels of
caspase-3 without considering IkB does not indicate the survival potential of cells.
Hence, we develop a simple metric that quantifies each investigated molecule’s
activity and evaluates their net effect: the CSM measures the relative difference in the
areaunder curve (AUC) forthe relative apoptotic and survival activities withtimefor
the k
th condition, i.e.
CSMk~aAUCSurvival
k {bAUC
Apoptosis
k ð6Þ
wherethesummationofAUCsforthesurvival(Eq.7)andapoptotic(Eq.8)molecules
are averaged:
AUCSurvival
k ~
1
3
AUCIkB,kzAUCp38,kzAUCJNK,k
  
ð7Þ
AUC
Apoptosis
k ~
1
2
AUCcaspase{8,kzAUCcaspase{3,k
  
ð8Þ
a and b are weight constants determined from the experimental data (see below).
Thus,positiveandnegativeCSMkdenotesnetsurvivalanddeath,respectively,forthe
k
th condition.
The relative difference in the AUC for the i
th molecule’s activity compared to
wildtype condition is noted:
AUCi,k~
Ð tmax
0 S^ IMi,kdt{
Ð tmax
0 S^ IMi,WTdt
Ð tmax
0 S^ IMi,WTdt
i[ IkB,p38,JNK,caspase   8,caspase   3 fg
ð9Þ
where S^ IMi,k is the normalized simulation values for the i
th molecule in the k
th
condition and tmax~120min. Note that we used the AUCs of our final model
simulations which fit well with all experimental conditions.
Next, we make a link between the CSM and SR. We note that CSMWT~0 (from
Eq. 6–8) and that the SR for each k
th condition is obtained from experimental data
22:
SR
experimental
WT
SR
experimental
FADDKD
SR
experimental
RIP1KD
SR
experimental
TRAF2KD
0
B B B B B @
1
C C C C C A
~
0:59
0:76
0:18
0:28
0
B B B @
1
C C C A
ð10Þ
Thus, we make an exponential relationship:
SRk~leCSMk ð11Þ
where for wildtype, eCSMWT ~1, and l indicates the basal net survival with
l~SR
experimental
WT ~0:59. Putting Eq. 11 into equation Eq. 6 and solving them simul-
taneously produces 3 possible solutions for a and b (since we have 2 parameters for 3
equations). For example, solving a and b using i) SR
experimental
FADDKD and SR
experimental
RIPKD ,w e
obtain evaluated (predicted) SR for TRAF2 KD, X KD and Y KD (Figure 7C). We
performed a and b using ii) SR
experimental
FADDKD and SR
experimental
TRAF2KD and iii) SR
experimental
RIPKD and
SR
experimental
TRAF2KD to predict SR for other conditions (Figure S1). Notably, among the 3
solutions, the most conservative survival ratios for the best candidate Z KD is,
SRevaluated
ZKD %0:05.
TRAIL model limitations. Like any other modeling approach, there are certain
limitations. Firstly, the perturbation-response approach discussed does not com-
prehensively represent the details of each signaling reaction’s kinetics. Secondly, the
small perturbation assumption leading to the first-order mass-action equations
represents an average cell response and this cannot be used to study single cell
stochastic behavior oroscillatory dynamics. Thirdly, the model predictions will show
relative,andnotabsolute,activationlevels.However,theapproachisnotrestrictedto
the TRAIL pathways and can be applied to model any pathways that experimentally
display formation and depletion waves, e.g. the TLRs
20, TNF
34 and EGF receptor
signaling
54.
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